Zhongji Longevity Science Group Co., Ltd. ("Zhongji Longevity") completed the subscription of new shares under the general authorization on June 6, 2024. The company announced that all preconditions have been met and a total of 91,088,258 new shares have been allocated and issued to subscribers at a subscription price of HKD 0.215 per share, raising a total of approximately HKD 19,584,000. After deducting related costs and expenses, the net amount is approximately HKD 19,384,000. The company plans to use 60% of the net proceeds to expand its existing longevity science business and new biomedical trading business, and the remaining 40% will be used for general working capital. After this share subscription, the company's total share capital increased to 546,529,549 shares, with Subscribers A, B, and C holding 5.53%, 8.51%, and 2.63% of the company's shares, respectively.

Zhongji Longevity Science Group Co., Ltd. ("Zhongji Longevity") completed the subscription of new shares under the general authorization on June 6, 2024. The company announced that all preconditions have been met and a total of 91,088,258 new shares have been allocated and issued to subscribers at a subscription price of HKD 0.215 per share, raising a total of approximately HKD 19,584,000. After deducting related costs and expenses, the net amount is approximately HKD 19,384,000. The company plans to use 60% of the net proceeds to expand its existing longevity science business and new biomedical trading business, and the remaining 40% will be used for general working capital. After this share subscription, the company's total share capital increased to 546,529,549 shares, with Subscribers A, B, and C holding 5.53%, 8.51%, and 2.63% of the company's shares, respectively.